BAP1 and breast carcinoma: Although loss of BAP1 function is seen at far lower rates in breast carcinoma (1%) (Stephens et al., 2012) and non-small cell lung carcinoma (1%) (Owen et al., 2017), the high incidence of these cancers translates to a large cohort of patients.